Analysis of the key themes driving M&A activity reveals that artificial intelligence accounted for 9 pharmaceutical deals announced in Q3 2023, worth a total value of $3m. The $2.7m acquisition of Humain Healthtech by PVP Ventures was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.

In value terms, artificial intelligence-related deal activity decreased by 99% in Q3 2023 compared with the previous quarter’s total of $456.7m and fell by 99% as compared to Q3 2022. Related deal volume increased by 29% in Q3 2023 versus the previous quarter and was 80% higher than in Q3 2022.

The top-ranked financial advisors supporting these M&A deals in Q3 2023 were Cohen; Excel Partners; Guggenheim Partners with 1, 1, 1 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q3 2023 were Wilson Sonsini Goodrich & Rosati Professional; Dentons Bingham Greenbaum; DLA Piper with 2, 1, 1 deals respectively.

For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.